multiple sclerosis/autoimmune diseases/type 1 diabetes/allergy therapeutic program (Toleranzia)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug Namemultiple sclerosis/autoimmune diseases/type 1 diabetes/allergy therapeutic program (Toleranzia)
Drug Alias NameCTA1R7K-X-DD based fusion protein (Toleranzia)CTA1R7K-X-DD based fusion protein (MIVAC)multiple sclerosis therapeutics (MIVAC/Synthon)multiple sclerosis therapeutics (Toleranzia/Synthon)
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionNeuroprotectants
TargetsUpdating
Therapy Area/IndicationsHypersensitivityAutoimmune DiseasesDiabetes Mellitus, Type 1 +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySwedenNetherlands
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesUniversity of Gothenburg
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMIVAC DevelopmentToleranzia ABSynthon Bv
Active IndicationsN/A
Inactive IndicationsHypersensitivityAutoimmune DiseasesDiabetes Mellitus, Type 1 +[4] 

Other Information

ATC CodeN/A
Related LinksN/A